biostudies-literatureMurray MMNational Institute of Arthritis and Musculoskeletal and Skin DiseasesNIAMS NIH HHS1843-1850https://www.ebi.ac.uk/biostudies/studies/S-EPMC8387392biostudies-literatureUnknown39(9)Anterior cruciate ligament (ACL) injuries occur at a high frequency in the United States with approximately 400,000 ACL reconstructions being performed each year. While ACL reconstruction is our current gold standard of treatment, it does not restore joint motion, or prevent the premature development of posttraumatic osteoarthritis (PTOA) in many patients. Thus, new treatments for an ACL injury, which are less invasive and minimize patient morbidity, including cartilage damage, are highly desirable. We have used a tissue-engineered approach to stimulate ligament healing, to improve upon current treatment options. In this review, we describe and discuss our work moving a tissue engineering strategy from the concept to bench, preclinical, clinical trials and ultimately FDA 510(k) de Novo approval, providing clinicians and patients with a viable alternative to ACL reconstruction.Journal of orthopaedic research : official publication of the Orthopaedic Research SocietyOptimizing outcomes of ACL surgery-Is autograft reconstruction the only reasonable option?PMC8387392R01‐AR056834R01 AR065462R01‐AR065462R01 AR056834Murray MMfalseOptimizing outcomes of ACL surgery-Is autograft reconstruction the only reasonable option?Anterior cruciate ligament (ACL) injuries occur at a high frequency in the United States with approximately 400,000 ACL reconstructions being performed each year. While ACL reconstruction is our current gold standard of treatment, it does not restore joint motion, or prevent the premature development of posttraumatic osteoarthritis (PTOA) in many patients. Thus, new treatments for an ACL injury, which are less invasive and minimize patient morbidity, including cartilage damage, are highly desirable. We have used a tissue-engineered approach to stimulate ligament healing, to improve upon current treatment options. In this review, we describe and discuss our work moving a tissue engineering strategy from the concept to bench, preclinical, clinical trials and ultimately FDA 510(k) de Novo approval, providing clinicians and patients with a viable alternative to ACL reconstruction.2021-01-01T00:00:00Z2021 Sep2024-12-04T12:31:05.606Z2024-12-04T12:31:05.606ZS-EPMC83873923419134410.1002/jor.25128